This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

cholic acid (Cholic Acid FGK®)

Reference No. 1696

Publication date:

Appraisal information

cholic acid (Cholic Acid FGK®) 50 mg capsule
cholic acid (Cholic Acid FGK®) 250 mg capsule

Company: FGK Representative Service GmbH
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 13/08/2014

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, cholic acid (Cholic Acid FGK®) cannot be endorsed for use within NHS Wales for the treatment of inborn errors in primary bile acid synthesis due to sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency, 2- (or α-) methylacyl-CoA racemase (AMACR) deficiency or cholesterol 7α-hydroxylase (CYP7A1) deficiency in infants, children and adolescents aged 1 month to 18 years and adults.
Statement of Advice (SOA)